607-91-0 | Sigma-Aldrich

S(–)-Blebbistatin: Selective inhibitor ofnon-muscle myosin II

al., Br. J. Pharmacol., 84, 595-607 (1985). 89. Narisada, M. et al., J. Med. Chem., 31, 1847-1854 (1988). 90. Lumley, P., et al., Br. J. Pharmacol., 97, 783-794 (1989). 91. Ogletree, M.L., et al., J. Pharmacol

MultiScreen 384-SEQ Filter Plate; Ready-to-use, automation-friendly, 384-well plate for dye terminator removal

Fax (01) 30.12.71.80 GERMANY Tel. (06196) 494-0 Fax (06196) 43901 HUNGARY Tel. 1-205 9784 Fax 1-205 9792 INDIA Tel. (91) 80-839 46 57 Fax (91) 80-839 63 45 ITALY Vimodrone (Milano): Tel.

Improved Assays for Quantification of In Vitro Vascular Permeability

0 0 0 ) 0 0 0 1 DMSO % in Growth Medium DMSO 42 0 0.1 TNF-α (ng/mL) 1001 2.5 5.0 7.5 10 Fl uo re sc

JULABO Catalog 2011 en

50 100 150 200 250 300 ˚C 0 ___TW20 0 20 40 60 80 100 120 -20 Supply temperature Internal reactor temperature min

Protocol: Ghrelin (Total) Radioimmunoassay (RIA) Kit

137 3 100 µL 1660 1660 100 75 µL 1330 1769 107 50 µL 934 1868 113 25 µL 607 2430 146

Protocol: Rat/Mouse Ghrelin (Active)

50 36 72% 154 102% 200 172 86% 285 91% 1,000

Protocol: Human PYY (Total) ELISA Kit - 96-Well Plate

80% 183 102% 500 490 83% 607 105% J 0 (BasaL) 92 -- 99 -- 40 125 83% 137 95% 100 182

Protocol- EZRGRA-90K

Rate Rat 0 (Basal) 0 - 53 - 50 60 96% 106 106% 200 200 94% 252 100% 1,000 885 102% 1,019 97% Rat 0 (Basal) 0 - 103 -

Protocol- EZHPYTT66K

124 108% 100 157 80% 183 102% 500 490 83% 607 105% J 0 (Basal) 92 - 99 - 40 125 83% 137 95% 100 182 90% 190 91% 500 557 93% 584 97%

Complex Carbohydrate Analysis- Enzymes, Kits and Reagents

Bangalore: (+91) 80 6621 9600 New Delhi: (+91) 11 4165 4255 Mumbai: (+91) 22 2570 2364 Hyderabad: (+91) 40 6684 5488 Fax Bangalore: (+91) 80 6621 9650 New Delhi: (+91) 11 4165 4266 Mumbai: (+91) 22 2579 7589

In Vitro Vascular Permeability Imaging Assay (Green)

antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ. Res. 87:603-607. 16. Bates DO et al. (2002) Regulation of microvascular permeability by vascular endothelial growth

Corticotropin-Releasing Factor Receptor Antagonists- Potential Novel Therapies for Human Disease

d e r : 1 . 8 0 0 . 3 2 5 . 3 0 1 0 ( U S ) T e c h n i c a l S

Biologics 32.3: NF-kB Activation: A Link Between Chronic Inflammation and Cancer

. No. PS1020 50 mg € 154 Anti-TORC2 (454-607) Rabbit pAb Liquid, undiluted serum. Immunogen used was a recombinant protein containing amino acids 454-607 of mouse TORC2 fused to GST. Recognizes the

MultiScreen® and Millicell® Filter Plates for Assay Development

less than 10%. * %CV = (SD/mean)*100. 1 2 3 4 A 599 601 649 605 B 509 649 631 598 C 584 607 609 618 D 619 550 605 625 C. Spot number by

XP725 Antibody List 013M4793

PRMT6 P6495 55170 PRMT6 NP_060607.1 P y n/d n/d 606 PRMT6 P2996 55170 PRMT6 NP_060607.1 M y n/d n/d 607 Proliferating Cell Protein Ki-67 P6834 4288 MKI67 NP_002408.3 M y n/d n/d 608 Protein Phosphatase 1α

XP725 Antibody List

PRMT6 P6495 55170 PRMT6 NP_060607.1 P y n/d n/d 606 PRMT6 P2996 55170 PRMT6 NP_060607.1 M y n/d n/d 607 Proliferating Cell Protein Ki-67 P6834 4288 MKI67 NP_002408.3 M y n/d n/d 608 Protein Phosphatase 1α